

Ketamine for Treatment-Resistant Anxiety: Should we be nervous?

Daniel Hong
PHARM 505B

References

- 1) McIntyre RS, Lipsitz O, Rodrigues NB, Lee Y, Cha DS, Vinberg M, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. *Bipolar Disord*. 2020;22(8):831–40.
- 2) McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LMW, et al. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. *J Psychopharmacol*. 2021;35(2):128–36.
- 3) Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to Ketamine. *J Clin Psychiatry*. 2014;75(9):e932–8.
- 4) Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. *J Psychopharmacol*. 2020;34(3):267–72.
- 5) Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, et al. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. *J Psychopharmacol*. 2017;31(10):1302–5.
- 6) Glue P, Neehoff SM, Medlicott NJ, Gray A, Kibby G, McNaughton N. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. *J Psychopharmacol*. 2018;32(6):663–7.
- 7) Loo CK, Gálvez V, O'Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. *Acta Psychiatr Scand*. 2016;134(1):48–56.
- 8) Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: A review of the literature. *CNS Spectr*. 2020;25(3):331–42.
- 9) Alshammari TK. The ketamine antidepressant story: New insights. *Molecules*. 2020;25(23).
- 10) Swainson J, Khullar A. Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression? *J Clin Psychiatry* 2020; 81:1.